I. MODIFIED AGREEMENTS

Biotech Co.*

Pharma Co.

Change

Disclosed

Terms/Details

(Symbol)

(Country)

from original

Funding

(Date)

agreement

($M)


Actelion Ltd.
(Switzerland)*

R.W. Johnson
Pharmaceutical
Research
Institute
(division of
Johnson &
Johnson)

Extended for a third year a collaboration to discover compounds targeting the vascular endothelium

ND

Actelion will continue to combine its base in vascular endothelium biology with expertise in medical chemistry to discover the compounds; Johnson & Johnson will develop and commercialize any new drugs arising from the project (6/25)

Alliance
Pharmaceutical
Corp.
(ALLP)

Baxter
Healthcare
Corp.

Modified agreement for Oxygent development

$30

Baxter will make a $4M investment in Series F preferred stock, as well as an additional $3M investment later in May; Baxter must make an additional investment of $23M by the end of September (5/2)

ComGenex
Inc.

(Hungary)*

Bayer AG
(Germany)

Extension of the companies' combinatorial supply agreement

ND

The extension will strive to increase the number of potentially bioactive compound libraries co-designed and delivered to Bayer (5/15)

GenVec
Inc.
(GNVC)

Varian
Medical
Systems Inc.

Extension to a collaboration made in 1998 for treatments of cancer

ND

Extension will last through 2004; collaborative agreement will combine advances in gene therapy products with targeted radiation therapy (6/20)

Neose
Technologies
Inc.
(NTEC)

Bristol-Myers
Squibb Co.

Research and development agreement reassigned to Progenics Pharmaceuticals Inc.

ND

The change is in connection with Progenics' reacquisition of development and marketing rights from BMS of two cancer vaccine programs; Progenics has the right to negotiate with Neose for the supply of the two gangliosides for use as the active pharmaceutical ingredients in the cancer vaccines (5/18)

Paradigm
Genetics Inc.
(PDGM)

Bayer AG
(Germany)

Extended and expanded research agreement to develop herbicides

$30

The five-year deal, worth up to $30M, is an extension to a $40M deal signed in 1998 (6/19)

Progenics Pharmaceuticals
Inc.
(PGNX)

F. Hoffmann-
La Roche Ltd.
(Switzerland)

Renewal of a research collaboration focused on the discovery and development of novel therapeutics

ND

The program aims to identify drugs that target HIV coreceptors (4/27)

Trimeris Inc.
(TRMS)

Hoffmann-
La Roche Inc.

Expanded agreement to discover and develop peptides

ND

Companies will develop novel generations of HIV fusion inhibitor peptides (6/19)

Zycos Inc.*

Aventis
Pasteur
(France)

Extended drug discovery collaboration on an undisclosed cancer antigen

ND

Collaboration was originally initiated in 1999; extended agreement provides Zycos with additional research and development payments, milestone payments and royalties on any commercialized products (6/25)

II. TERMINATED AGREEMENTS

BioCryst
Pharmaceuticals
Inc.
(BCRX)

Ortho-McNeil
Pharmaceuticals
Inc. and R.W.
Johnson
Pharmaceutical Research Institute

Terminated worldwide license agreement for the flu treatment, RWJ-270201

ND

Termination returns to BioCryst rights to the influenza neuraminidase inhibitors; Ortho-McNeil will maintain any work in progress for the next four months (4/30)

Digene Corp.
(DIGE)

Abbott
Laboratories
Inc.

Terminated marketing and distribution agreement for Digene's human papillomavirus DNA tests and accessories

ND

Abbott and Digene terminated their agreement (5/2)

Genentech Inc.
(NYSE:DNA)

Schwarz
Pharma AG
(Germany)

Terminated agreement of rights to two growth hormone products, Nutropin AQ and Nutropin Depot

ND

Genentech reaacquired rights to the products in Europe and certain other countries outside Canada, the U.S., China and Japan (6/8)

Peregrine
Pharmaceuticals
Inc.
(PPHM)

Schering AG
(Germany)

Terminated development agreement for Oncolym

ND

Peregrine negotiated with Schering to take back development of Oncolym, which was licensed to Schering in March 1999 (6/8)

Pharmacyclics
Inc.
(PCYC)

Nycomed
Amersham
plc

Terminated rights agreement for Lutrin

$2.75

Termination returns worldwide rights to Pharmacyclics; the company now has worldwide rights in Eruope, Asia, and South and Central America; Amersham will pay a one-time $2.75M fee to cover future research and development obligations (5/4)

Progenics
Pharmaceuticals
Inc.
(PGNX)

Bristol-
Myers Squibb
Co.

Terminated collaboration for GMK and MGV cancer vaccines

$15.5

The companies are terminating their agreement to develop the vaccines; Progenics will receive $15.5M and regain all rights to the products (5/15)


NOTES

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchang; VSE = Vancouver Stock Exchange.

No Comments